References
- McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006; 26: 154–8; PMID:16789469
- Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. A personalized view on cancer immunotherapy. Cancer Lett 2014; 352: 113–25; PMID:24051308; http://dx.doi.org/10.1016/j.canlet.2013.09.016
- Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014; 20: 1747–56; PMID:24691639; http://dx.doi.org/10.1158/1078-0432.CCR-13-2116
- Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D, Van Lint S, Heirman C, Thielemans K, Breckpot K. Targeting the tumor environment to enhance antitumor immune responses. Oncotarget 2015; 6(3):1359–1381.
- Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010; 21 Suppl 7: vii339–44; PMID:20943639
- Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee HG, Garbe C, Pascolo S. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31: 180–8; PMID:18481387; http://dx.doi.org/10.1097/CJI.0b013e31815ce501
- Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, Breckpot K, Thielemans K. The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines 2015; 14(2): 235–251.
- Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K. mRNA-based dendritic cell vaccines. Expert Rev Vaccines 2015: 14(2): 161–167.
- Van Lint S. Development of a local treatment modality for the systemic cure of cancer using mRNA as a medicinal product. 1st ed. Brussels: VUB Press; 2014.
- Van der Jeught K, Joe PT, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, Escors D, Thielemans K, Breckpot K. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget 2014; 5: 10100–13; PMID:25338019